Story

Legend Biotech Stock Slides Despite First-Ever Profit and Earnings Beat

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Legend Biotech Stock Slides Despite First-Ever Profit and Earnings Beat
Text size
Background

Legend Biotech (NASDAQ: LEGN) shares fell 2.4% in pre-market trading despite the company reporting its first quarter of company-wide profitability and beating analyst expectations for the second quarter of 2026. The decline illustrates a classic "sell the news" dynamic, where strong results were overshadowed by mounting analyst concerns and recent leadership changes.

Strong Quarter Meets Muted Reception

Legend Biotech announced a significant financial milestone, achieving its first-ever profitable quarter. The company posted an adjusted earnings per share (EPS) of $0.16, more than double the Wall Street consensus estimate of $0.07. Revenue also surpassed expectations, coming in at $387.5 million against a forecast of $362.81 million.

Despite the strong performance, the stock's muted reaction suggests the positive results may have already been priced in by investors following a significant run-up from its 52-week low. The selling pressure indicates that forward-looking concerns are currently outweighing the reported historical performance.

Analyst Downgrades and Competitive Headwinds

Sample IUX Markets – In-articleAd

Adding to the selling pressure, Oppenheimer recently downgraded Legend Biotech stock to Perform from Outperform, slashing its price target to $40 from $75, according to Investing.com. This move followed a series of cautious actions from other analysts in recent weeks.

Both UBS and JPMorgan previously cited growing competitive threats to CARVYKTI, the company's key CAR-T therapy, and a lack of clear near-term positive catalysts for the stock. Investor sentiment has also been unsettled by a leadership vacuum following the CEO's departure in late July, adding another layer of uncertainty.

Company-Specific Pressure

The weakness in Legend Biotech shares was specific to the company, not a reflection of broader market trends. During the same pre-market session, the S&P 500 and Nasdaq were trading higher. This divergence highlights that investors are focused on the combination of the high-profile analyst downgrade, unresolved leadership questions, and the competitive outlook for CARVYKTI.

Read next

More on Stocks
Back to latest news

LATEST